Monopar Therapeutics Inc. (MNPR) Earnings History
Annual and quarterly earnings data from 2015 to 2024
Loading earnings history...
MNPR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MNPR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export MNPR earnings history in CSV or JSON format
Free sign-in required to download data
Monopar Therapeutics Inc. (MNPR) Earnings Overview
As of May 8, 2026, Monopar Therapeutics Inc. (MNPR) reported trailing twelve-month net income of -$19M, reflecting -134.5% year-over-year growth. The company earned $-2.73 per diluted share over the past four quarters.
Looking at the long-term picture, MNPR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$687,000 in fiscal 2015.
Monopar Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CLDX (-$259M net income, -17253.3% margin), IMVT (-$464M net income), TPVG (-$12M net income, 50.6% margin), MNPR has comparable earnings metrics. Compare MNPR vs CLDX →
MNPR Earnings vs Peers
Earnings metrics vs comparable public companies
MNPR Historical Earnings Data (2015–2024)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$16M | -85.5% | -$16M | $-1.36 | - | - |
| 2023 | -$8M | +20.1% | -$9M | $-0.58 | - | - |
| 2022 | -$11M | -15.5% | -$11M | $-0.83 | - | - |
| 2021 | -$9M | -44.4% | -$9M | $-0.73 | - | - |
| 2020 | -$6M | -49.2% | -$7M | $-0.58 | - | - |
| 2019 | -$4M | -30.9% | -$4M | $-0.40 | - | - |
| 2018 | -$3M | +80.5% | -$3M | $-0.31 | - | - |
| 2017 | -$17M | -1296.3% | -$17M | $-1.59 | - | - |
| 2016 | -$1M | -72.6% | -$1M | $-0.12 | - | - |
| 2015 | $-687,000 | - | $-689,000 | $-0.08 | - | - |
See MNPR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MNPR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MNPR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMNPR — Frequently Asked Questions
Quick answers to the most common questions about buying MNPR stock.
Is MNPR growing earnings?
MNPR EPS fell to $-2.73, with earnings declining -134.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-19M.
What are MNPR's profit margins?
Monopar Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MNPR's earnings?
MNPR earnings data spans 2015-2024. The declining earnings trend is -134.5% YoY. Historical data enables comparison across business cycles.